Clinical and commercial quality controls are eased as the FDA looks to expedite therapy approvals in areas of unmet need.

Common pollutants are disrupting energy production at the cellular level in wild seabirds, potentially affecting fitness, new ...

CAR-T therapy is a major advance in cancer care, but high costs and centralized global manufacturing limit access.

Reliance Industries pauses its plans to manufacture lithium-ion cells in India amid challenges in securing technology ...

Reliance Industries Ltd. has halted its plans to manufacture lithium-ion battery cells in India due to the inability to ...

This move aims to meet growing domestic and international demand. Premier Energies will also venture into ingot and wafer ...

During its second-quarter earnings call, Reliance had said it was rapidly constructing both its battery and electrolyser giga ...

Cellares, the contract drugmaker known for its cell therapy factory-in-a-box, will expand its operations to Europe after ...

Gujarat is leading India's solar cell manufacturing with significant investments and capacity expansions, positioning itself ...

Reliance Industries Ltd has paused plans to make lithium-ion battery cells in India after failing to secure Chinese ...

India’s Reliance Industries said on Monday that its plans for battery storage manufacturing remain unchanged, following a ...

FDA Commissioner Marty Makary called these changes “common-sense reforms” that could expedite the development of cell and ...